Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Public, Subsidiary
- Established
- 2002-01-25
- Employees
- 1K
- Market Cap
- -
- Website
- https://www.3s-guojian.com
The Study of Drug 601 in Patients With Wet Age-related Macular Degeneration (wAMD)
- Conditions
- Wet Age-related Macular Degeneration
- Interventions
- Drug: Drug 601
- First Posted Date
- 2020-07-13
- Last Posted Date
- 2020-07-13
- Target Recruit Count
- 67
- Registration Number
- NCT04468997
- Locations
- 🇨🇳
BeiJing Hospital, Beijing, China
Efficacy and Safety Study of Combination of CPGJ602 and Chemotherapy, in First Line, With Wild KRAS/NRAS/BRAF in Metastatic Colorectal Cancer
- First Posted Date
- 2020-07-10
- Last Posted Date
- 2021-08-23
- Target Recruit Count
- 75
- Registration Number
- NCT04466254
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, Beijing, China
Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-5 Humanized Monoclonal Antibody Injection
- Conditions
- add-on Maintenance Treatment of Patients With Severe Eosinophilic Asthma
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2021-01-28
- Target Recruit Count
- 52
- Registration Number
- NCT04445038
- Locations
- 🇨🇳
Shanghai General Hospital, Shanghai, Shanghai, China
Randomized, Double Blinded, Placebo Controlled, Single Dose Escalation Study of 608 in Healthy Subjects
- First Posted Date
- 2020-04-29
- Last Posted Date
- 2020-04-29
- Target Recruit Count
- 62
- Registration Number
- NCT04367441
- Locations
- 🇨🇳
Public Health Clinical Center (Shanghai), Jinshan, Shanghai, China
Safety and Efficacy Study of Prefilled Liquid Etanercept(Yisaipu) for Active Ankylosing Spondylitis
- Conditions
- Ankylosing Spondylitis
- Interventions
- Drug: prefilled liquid etanercept(Yisaipu)
- First Posted Date
- 2020-04-14
- Last Posted Date
- 2020-04-14
- Target Recruit Count
- 640
- Registration Number
- NCT04345458
- Locations
- 🇨🇳
Chinese PLA General Hospital clinical trial center, Beijing, Beijing, China
The Study of Drug 601 in Patients With Diabetic Macular Edema (DME)
- Conditions
- Diabetic Macular Edema
- Interventions
- Drug: Drug 601
- First Posted Date
- 2019-11-05
- Last Posted Date
- 2019-11-05
- Target Recruit Count
- 50
- Registration Number
- NCT04151407
- Locations
- 🇨🇳
Chinese PLA General Hospital of Central Theater., Wuhan, Hubei, China
🇨🇳JiangSu Province Hospital, Nanjing, Jiangsu, China
🇨🇳Shanghai General Hospital, Shanghai, Shanghai, China
Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A in China
- First Posted Date
- 2019-06-26
- Last Posted Date
- 2020-09-09
- Target Recruit Count
- 24
- Registration Number
- NCT03998345
- Locations
- 🇨🇳
Cancer hospital Chinese academy of medical sceience, Beijing, Beijing, China
Pharmacokinetics, Efficacy and Safety of the 304 Injection
- First Posted Date
- 2019-06-10
- Last Posted Date
- 2019-06-10
- Target Recruit Count
- 60
- Registration Number
- NCT03980379
- Locations
- 🇨🇳
The 307 Hospital of People's Liberation Army, Beijing, Beijing, China
🇨🇳Beijing Luhe Hospital Capital Medical University, Beijing, Beijing, China
🇨🇳Sun Yat-Sen University Cancer Hospital, Guangzhou, Guangdong, China
Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A
- First Posted Date
- 2019-05-15
- Last Posted Date
- 2020-04-03
- Target Recruit Count
- 24
- Registration Number
- NCT03950297
- Locations
- 🇺🇸
NEXT Oncology Business Office, San Antonio, Texas, United States
A Study of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Metastatic Colorectal Cancer
- Conditions
- Metastatic Colorectal Cancer
- First Posted Date
- 2017-11-29
- Last Posted Date
- 2018-09-17
- Target Recruit Count
- 21
- Registration Number
- NCT03356158
- Locations
- 🇨🇳
Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China